BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 20171417)

  • 1. Diffusion of a new drug: a comparative analysis of adoption, treatment complexity, and persistence of risperidone long-acting injectable therapy in the Netherlands.
    Pechlivanoglou P; Vehof J; van Agthoven M; de Jong-van den Berg LT; Postma MJ
    Clin Ther; 2010 Jan; 32(1):108-18. PubMed ID: 20171417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors for starting depot administration of risperidone in chronic users of antipsychotics.
    Vehof J; Postma MJ; Bruggeman R; De Jong-Van Den Berg LT; Van Den Berg PB; Stolk RP; Burger H
    J Clin Psychopharmacol; 2008 Dec; 28(6):625-30. PubMed ID: 19011430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Explicit review of risperidone long-acting injection prescribing practice.
    Wheeler A; Vanderpyl J; Carswell C; Stojkovic M; Robinson E
    J Clin Pharm Ther; 2011 Dec; 36(6):651-63. PubMed ID: 22023342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome.
    Weiden PJ; Schooler NR; Weedon JC; Elmouchtari A; Sunakawa A; Goldfinger SM
    J Clin Psychiatry; 2009 Oct; 70(10):1397-406. PubMed ID: 19906343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment retention with risperidone long-acting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry (e-STAR) in six countries.
    Peuskens J; Olivares JM; Pecenak J; Tuma I; Bij de Weg H; Eriksson L; Resseler S; Akhras K; Jacobs A
    Curr Med Res Opin; 2010 Mar; 26(3):501-9. PubMed ID: 20014981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switching to long-acting injectable risperidone is beneficial with regard to clinical outcomes, regardless of previous conventional medication in patients with schizophrenia.
    Marinis TD; Saleem PT; Glue P; Arnoldussen WJ; Teijeiro R; Lex A; Latif MA; Medori R
    Pharmacopsychiatry; 2007 Nov; 40(6):257-63. PubMed ID: 18030649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable.
    Parellada E; Andrezina R; Milanova V; Glue P; Masiak M; Turner MS; Medori R; Gaebel W
    J Psychopharmacol; 2005 Sep; 19(5 Suppl):5-14. PubMed ID: 16144781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Switching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone: reasons for switching and safety.
    Hawley C; Turner M; Latif MA; Curtis V; Saleem PT; Wilton K
    Hum Psychopharmacol; 2010 Jan; 25(1):37-46. PubMed ID: 20041474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. One-year treatment continuation in patients prescribed risperidone long-acting injection in New Zealand: a retrospective study.
    Wheeler A; Vanderpyl J; Carswell C; Stojkovic M; Robinson E
    Clin Schizophr Relat Psychoses; 2012 Jul; 6(2):61-8. PubMed ID: 22776632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone: efficacy, quality of life and functional outcome.
    Lloyd K; Latif MA; Simpson S; Shrestha KL
    Hum Psychopharmacol; 2010 Apr; 25(3):243-52. PubMed ID: 20373476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does oral antipsychotic pre-treatment influence outcome of a switch to long-acting injectable risperidone in patients with schizophrenia?
    Schmauss M; Diekamp B; Gerwe M; Schreiner A; Ibach B
    Pharmacopsychiatry; 2010 Mar; 43(2):73-80. PubMed ID: 20131207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The combined use of risperidone long-acting injection and clozapine in patients with schizophrenia non-adherent to clozapine: a case series.
    Se Hyun Kim ; Dong Chung Jung ; Yong Min Ahn ; Yong Sik Kim
    J Psychopharmacol; 2010 Jul; 24(7):981-6. PubMed ID: 19942641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experience with injectable long-acting risperidone in long-term therapy after an acute episode of schizophrenia: the SPHERE Study.
    De la Gándara J; San Molina L; Rubio G; Rodriguez-Morales A; Hidalgo Borrajo R; Burón JA
    Expert Rev Neurother; 2009 Oct; 9(10):1463-74. PubMed ID: 19831836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of long-acting injectable risperidone in daily practice: an open-label, noninterventional, prospective study in schizophrenia and related disorders.
    Parellada E; Kouniakis F; Siurkute A; Schreiner A; Don L
    Int Clin Psychopharmacol; 2010 May; 25(3):149-54. PubMed ID: 20305567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prescribing patterns of antipsychotics in 13 French psychiatric hospitals].
    Bret P; Bret MC; Queuille E
    Encephale; 2009 Apr; 35(2):129-38. PubMed ID: 19393381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risperidone long-acting injection (RLAI): the 12-week efficacy and tolerability in Thai patients with chronic schizophrenia.
    Arunpongpaisal S; Srisurapanont M; Kongsakon R; Kitiwattanagul K; Samanwongthai U
    J Med Assoc Thai; 2010 Mar; 93(3):343-50. PubMed ID: 20420110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of long-acting injectable risperidone versus oral antipsychotics in the treatment of recent-onset schizophrenia: a case-control study.
    Barrio P; Batalla A; Castellví P; Hidalgo D; García M; Ortiz A; Grande I; Pons A; Parellada E
    Int Clin Psychopharmacol; 2013 Jul; 28(4):164-70. PubMed ID: 23587986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risperidone long-acting injection in Schizophrenia Spectrum Illnesses compared to first generation depot antipsychotics in an outpatient setting in Canada.
    Lammers L; Zehm B; Williams R
    BMC Psychiatry; 2013 May; 13():155. PubMed ID: 23718192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risperidone long-acting injectable (Risperdal Consta®) for maintenance treatment in patients with bipolar disorder.
    Bobo WV; Shelton RC
    Expert Rev Neurother; 2010 Nov; 10(11):1637-58. PubMed ID: 20977322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.